Published in Br J Rheumatol on April 01, 1995
Avascular necrosis of humeral head in an elderly patient with tuberculosis: a case report. J Med Case Rep (2008) 0.75
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell (1994) 4.50
Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature (1986) 4.24
Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol (2001) 3.12
Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem J (1984) 2.47
Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol (2000) 2.45
p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem (1999) 2.38
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
A cartilage catabolic factor from synovium. Biochem J (1979) 2.11
The 3' untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol Cell Biol (2001) 2.09
Prevalence of radiographic osteoarthritis--it all depends on your point of view. Rheumatology (Oxford) (2006) 1.94
Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) (2001) 1.70
Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med (1985) 1.70
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) (2000) 1.67
Regulation of tumour necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett (2000) 1.66
Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol (1997) 1.64
Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol (1986) 1.64
Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. J Biol Chem (1992) 1.57
Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol (2001) 1.55
Purification to homogeneity of pig leucocyte catabolin, a protein that causes cartilage resorption in vitro. Biochem J (1983) 1.54
A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett (1998) 1.52
Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J Exp Med (1986) 1.50
Characterization of catabolin, the major product of pig synovial tissue that induces resorption of cartilage proteoglycan in vitro. Biochem J (1981) 1.46
Identification of catabolin, a protein fro synovium which induces degradation of cartilage in organ culture. Biochem Biophys Res Commun (1980) 1.45
Identification of a common class of high affinity receptors for both types of porcine interleukin-1 on connective tissue cells. Nature (1987) 1.45
Interleukin-1. Int J Biochem Cell Biol (1998) 1.44
Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol (1996) 1.42
Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol (1998) 1.40
FGF-2 is bound to perlecan in the pericellular matrix of articular cartilage, where it acts as a chondrocyte mechanotransducer. Osteoarthritis Cartilage (2007) 1.40
How does interleukin 1 activate cells? Interleukin 1 signal transduction. Immunol Today (1990) 1.37
IL-1 and TNF transmodulate epidermal growth factor receptors by a protein kinase C-independent mechanism. J Immunol (1989) 1.33
Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum (1993) 1.30
p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol (1998) 1.26
The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol (1991) 1.25
HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. J Rheumatol (2001) 1.25
T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem (1997) 1.24
Identification of proteinases in rheumatoid synovium. Detection of leukocyte elastase cathepsin G and another serine proteinase. Biochim Biophys Acta (1980) 1.21
The reliability of the three-dimensional FASTRAK measurement system in measuring cervical spine and shoulder range of motion in healthy subjects. Rheumatology (Oxford) (2000) 1.19
Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. Proc Natl Acad Sci U S A (1996) 1.19
Radiographic patterns and response to corticosteroid hip injection. Ann Rheum Dis (1997) 1.18
Coeliac disease presenting as recurrent pericarditis. Lancet (1981) 1.18
Down-modulation of epidermal growth factor receptor affinity in fibroblasts treated with interleukin 1 or tumor necrosis factor is associated with phosphorylation at a site other than threonine 654. J Biol Chem (1990) 1.18
The chemotactic factor N-formylmethionyl-leucyl-phenylalanine activates microtubule-associated protein 2 (MAP) kinase and a MAP kinase kinase in polymorphonuclear leucocytes. Biochem J (1993) 1.17
Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q J Med (1985) 1.17
Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum (2001) 1.17
Clinical value of ELISA assays for IgM and IgG rheumatoid factors. J Clin Pathol (1987) 1.15
Interleukin-1 beta and interleukin-1 alpha stimulate the plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum (1987) 1.14
Transforming growth factor beta 1 and interleukin 4 induced alpha smooth muscle actin expression and myofibroblast-like differentiation in human synovial fibroblasts in vitro: modulation by basic fibroblast growth factor. Ann Rheum Dis (1997) 1.14
Pig interleukin 1 (catabolin) is a potent stimulator of bone resorption in vitro. Calcif Tissue Int (1985) 1.13
Characterization of proteins from human synovium and mononuclear leucocytes that induce resorption of cartilage proteoglycan in vitro. Biochem J (1983) 1.12
Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy. Ann Rheum Dis (1986) 1.11
Lymphocytes induce resorption of cartilage by producing catabolin. Biochem J (1982) 1.11
Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol (1996) 1.10
Interleukin 1 and tumour necrosis factor increase phosphorylation of fibroblast proteins. FEBS Lett (1988) 1.09
Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. J Biol Chem (1998) 1.08
Interleukin 1 and tumor necrosis factor stimulate two novel protein kinases that phosphorylate the heat shock protein hsp27 and beta-casein. J Biol Chem (1993) 1.08
Selective activation of JNK/SAPK by interleukin-1 in rabbit liver is mediated by MKK7. FEBS Lett (1997) 1.07
Serum matrix metalloproteinase 3 as a predictor of joint destruction in rheumatoid arthritis: comment on the article by Yamanaka et al. Arthritis Rheum (2000) 1.07
The GALS locomotor screen and disability. Ann Rheum Dis (1993) 1.07
Interleukin 1 and tumour necrosis factor increase phosphorylation of the small heat shock protein. Effects in fibroblasts, Hep G2 and U937 cells. FEBS Lett (1989) 1.06
Evidence of two mechanisms for the activation of the glucose transporter GLUT1 by anisomycin: p38(MAP kinase) activation and protein synthesis inhibition in mammalian cells. J Physiol (1997) 1.05
Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol (1989) 1.04
Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Ann Rheum Dis (1999) 1.01
Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. Eur J Clin Pharmacol (1986) 1.01
Murine interleukin-1 receptor: differences in binding properties between fibroblastic and thymoma cells and evidence for a two-chain receptor model. FEBS Lett (1987) 1.01
Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis (1994) 1.01
Gonococcal arthritis: an unusual presentation as pseudothrombophlebitis. Ann Rheum Dis (1985) 1.00
Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol (1994) 0.99
Murine interleukin 1 receptor. Direct identification by ligand blotting and purification to homogeneity of an interleukin 1-binding glycoprotein. J Biol Chem (1988) 0.99
Inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by a lipophilic inactivator of cysteine endopeptidases. Biochem J (1992) 0.99
Interleukin 1 stimulates hexose transport in fibroblasts by increasing the expression of glucose transporters. J Biol Chem (1990) 0.99
Spontaneous haemarthrosis following thrombolytic therapy for myocardial infarction. Postgrad Med J (1990) 0.97
Interleukin 1 alpha activates two forms of p54 alpha mitogen-activated protein kinase in rabbit liver. J Exp Med (1994) 0.96
Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) (2002) 0.96
Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) (2004) 0.95
High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol (2000) 0.95
How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol (2000) 0.94
Tissue typing in brucellosis. Ann Rheum Dis (1985) 0.94
Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) (2005) 0.94
Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) (2002) 0.93
Interleukin-1 activates a novel protein kinase that phosphorylates the epidermal-growth-factor receptor peptide T669. Biochem J (1994) 0.92
Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun (2004) 0.92
Medical audit: the differing perspectives of managers and clinicians. J R Coll Physicians Lond (1992) 0.92
The cartilage-resorbing protein catabolin is made by synovial fibroblasts and its production is increased by phorbol myristate acetate. Biochem J (1983) 0.91
Development and preliminary assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for routine clinical use. QJM (1995) 0.90
Primary care--the educational need. Br J Rheumatol (1990) 0.90
Interleukin-1 inhibits the synthesis of collagen by fibroblasts. Biochem Int (1986) 0.89
Interleukin-1 alpha modulates collagen gene expression in cultured synovial cells. Biochem J (1988) 0.89
Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol (1991) 0.89
Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M. Rheumatology (Oxford) (2006) 0.88
Phosphorylated HSP27 associates with the activation-dependent cytoskeleton in human platelets. Blood (1994) 0.88
Demonstration of cytokeratin in endothelial cells of the synovial microvasculature in situ and in vitro. Br J Rheumatol (1993) 0.87
Massive eosinophilia in rheumatoid arthritis: report of four cases. Clin Rheumatol (1986) 0.87
Neutral protease from the polymorphonuclear leucocytes of human rheumatoid synovial fluid. Clin Sci Mol Med (1974) 0.87
Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation. Biochem J (1992) 0.87